R Lepeule1, V Leflon-Guibout2, D Vanjak3, J-R Zahar4, M Lafaurie5, C Besson6, A Lefort7. 1. Unité transversale de traitement des infections, département de virologie, bactériologie-hygiène, parasitologie-mycologie, hôpital Henri-Mondor, AP-HP, 94010 Créteil, France. Electronic address: raphael.lepeule@hmn.aphp.fr. 2. Service de microbiologie, hôpital Beaujon, hôpitaux universitaires Paris Nord Val-de-Seine, AP-HP, Clichy, France. 3. Unité de contrôle des infections, institut Curie, Paris, France. 4. Unité de prévention et de lutte contre les infections nosocomiales, CHU d'Angers - Université d'Angers, Angers, France. 5. Unité d'intervention en infectiologie, hôpital Saint-Louis, AP-HP, Paris, France. 6. Service de microbiologie clinique, hôpital Européen Georges-Pompidou, AP-HP, Paris, France. 7. Service de médecine interne, hôpital Beaujon, hôpitaux universitaires Paris Nord Val-de-Seine, AP-HP, Clichy, France; IAME, UMR1137, université Paris-Diderot, Sorbonne Paris Cité, Paris, France; EA3964, faculté de médecine Xavier-Bichat, université Paris-Diderot, Paris, France.
Abstract
OBJECTIVE: We wanted to describe the clinical features associated with urinalysis positive for ESBL-producing Escherichia coli and their impact on antibiotic use. METHODS: We performed a prospective observational study in 13 French hospitals of the Paris area for 3 consecutive months. We included all patients with urine cultures positive for ESBL-producing E. coli. RESULTS: One hundred and seventeen of the 218 patients (54%) presented with asymptomatic bacteriuria, 31 (14%) with cystitis, and 70 (32%) with a parenchymal infection. Nineteen patients with asymptomatic bacteriuria (16%) received antibiotics. Forty-one with parenchymal infections (59%) received a carbapenem. A carbapenem alternative could have been used in every patient treated with a carbapenem, according to antibiotic susceptibility testing results. CONCLUSIONS: Urinary tract infections accounted for 46% of E. coli ESBL positive urinalysis. Fifty percent of parenchymal infections were treated with a carbapenem.
OBJECTIVE: We wanted to describe the clinical features associated with urinalysis positive for ESBL-producing Escherichia coli and their impact on antibiotic use. METHODS: We performed a prospective observational study in 13 French hospitals of the Paris area for 3 consecutive months. We included all patients with urine cultures positive for ESBL-producing E. coli. RESULTS: One hundred and seventeen of the 218 patients (54%) presented with asymptomatic bacteriuria, 31 (14%) with cystitis, and 70 (32%) with a parenchymal infection. Nineteen patients with asymptomatic bacteriuria (16%) received antibiotics. Forty-one with parenchymal infections (59%) received a carbapenem. A carbapenem alternative could have been used in every patient treated with a carbapenem, according to antibiotic susceptibility testing results. CONCLUSIONS: Urinary tract infections accounted for 46% of E. coli ESBL positive urinalysis. Fifty percent of parenchymal infections were treated with a carbapenem.
Authors: O Senard; M Lafaurie; P Lesprit; Y Nguyen; X Lescure; A Therby; V Fihman; N Oubaya; R Lepeule Journal: Eur J Clin Microbiol Infect Dis Date: 2019-09-11 Impact factor: 3.267
Authors: L Surgers; A Boyd; P-Y Boelle; V Lalande; P-A Jolivot; P-M Girard; G Arlet; C Cambier; A Homor; D Decre; J-L Meynard Journal: Eur J Clin Microbiol Infect Dis Date: 2017-02-08 Impact factor: 3.267